INO & REGN: some charts might be worth a lot of money
The long-term trend charts of INO & REGN are presented side by side for observation and conclusions.
Oppenheimer analyst Hartaj Singh recently initiated coverage on INO with an Outperform (Buy) and a price target of $35.
Singh admits that revenues at Inovio over the past three years have been measured in the low single digits of millions of dollars.
It won’t be until next year, says the analyst before sales really grow appreciably. But once INO’s vaccines begin coming to market,
the analyst sees significant growth potential:
$656 million in sales in 2022, twice that in 2023, $2.1 billion in 2024, and $3 billion in 2025.
Indeed, by 2025, the analyst forecasts that Inovio could be earning $6.48 per share, per year, making today’s price target of $35
(not to mention today’s actual share price of $15) look cheap indeed. And indeed, that’s probably why the analyst is rating the stock
“outperform” and recommending that investors buy it. (Previous information about Singh from TipRanks)
Having in mind these forecasts of Singh, who also covers Regeneron, one observing the two charts can draw very useful
(and probably very profitable) conclusions for INO’s stock course the next years.
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
Oppenheimer analyst Hartaj Singh recently initiated coverage on INO with an Outperform (Buy) and a price target of $35.
Singh admits that revenues at Inovio over the past three years have been measured in the low single digits of millions of dollars.
It won’t be until next year, says the analyst before sales really grow appreciably. But once INO’s vaccines begin coming to market,
the analyst sees significant growth potential:
$656 million in sales in 2022, twice that in 2023, $2.1 billion in 2024, and $3 billion in 2025.
Indeed, by 2025, the analyst forecasts that Inovio could be earning $6.48 per share, per year, making today’s price target of $35
(not to mention today’s actual share price of $15) look cheap indeed. And indeed, that’s probably why the analyst is rating the stock
“outperform” and recommending that investors buy it. (Previous information about Singh from TipRanks)
Having in mind these forecasts of Singh, who also covers Regeneron, one observing the two charts can draw very useful
(and probably very profitable) conclusions for INO’s stock course the next years.
Prompt: New traders should take some time and carefully read the post entitled 'You can't beat the market' that is located in my profile.
Disclaimer
The author of this text is not an investment advisor. The preceding content is intended to be used for informational and educational purposes only.
It is not an advice or inducement for the purchase or sale of the products mentioned. Before making any investment based on your own personal circumstances,
it is very important to do your own research and analysis and also take independent financial advice from a professional to verify any information provided here.
